Skip to main content
. 2013 Oct 29;109(12):2998–3004. doi: 10.1038/bjc.2013.662

Figure 2.

Figure 2

Survival distribution according to best response during first-line VEGF-targeted therapy. Patients achieving objective tumour remission (CR and PR) under first-line VEGF-targeted therapy had a median OS of 36 months compared with 31 months in patients with stable disease (P=0.217; 95% CI 26.1–38.1). Altogether, patients with a PR, SD and PD had a median OS of 31, 31.2 and 15.7 months, respectively.